EUVIMEDEUVIMED entdecken
Open Access

A pilot study of [68Ga]Ga-fibroblast activation protein inhibitor-04 PET/CT in renal cell carcinoma

Chunmei Guo, Ya Liu, Haozhou Yang, Yuxiao Xia, Xue Li, Liming Chen, Yue Feng, Yan Zhang, Yue Chen, Zhanwen Huang iD

British Journal of Radiology · 2024

DOI: 10.1093/bjr/tqae025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Radiology, 2024. Verfasst von Chunmei Guo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Young Talent Program of China National Nuclear Corporation, Sichuan Science and Technology Innovation and Entrepreneurship Seedling, Natural Science Foundation of Chengdu Medical College.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

As a promising positron emission tomography (PET) tracer, [68Ga]Ga-fibroblast activation protein inhibitor-04([68Ga]Ga-FAPI-04) performs better than 2-[18F]fluoro-2-deoxy-d-glucose ([18F]FDG) at diagnosing primary and metastatic lesions in patients with various types of cancer. We investigated the utility of [68Ga]Ga-FAPI-04 PET/CT for the detection of primary and metastatic lesions in renal cell carcinoma (RCC). [18F]FDG PET/CT were used for comparison.

Methods

Twenty-two patients with suspected RCC or recurrent RCC were enrolled in our study. Among these patients, 14 were newly diagnosed with RCC, 3 had recurrent RCC, and 5 were excluded from further analysis due to having benign renal tumours. Seventeen patients with RCC underwent [68Ga]Ga-FAPI-04 PET/CT, and 6 of them also received [18F]FDG PET/CT. The positive detection rates were calculated and compared with those in patients who underwent both scans.

Results

Data from 17 patients with RCC (median age: 60.5 years, interquartile range [IQR]: 54-70 years) were evaluated. The positive detection rate of [68Ga]Ga-FAPI-04 PET/CT for RCC was 64.7% (11/17). Lymph node metastases (n = 44), lung metastasis (n = 1), and bone metastasis (n = 1) were detected. Six patients with RCC underwent [68Ga]Ga-FAPI-04 and [18F]FDG PET/CT. [68Ga]Ga-FAPI-04 PET/CT showed a higher positive detection rate than [18F]FDG PET/CT in detecting RCC (83.3% [5/6] vs. 50% [3/6], P = 0.545). Additionally, [68Ga]Ga-FAPI-04 PET/CT has higher SUVmax (3.20 [IQR: 2.91-5.80 vs. 2.71 [IQR: 2.13-3.10], P = 0.116) and tumour-to-background ratio (TBR) values (1.60 [IQR: 1.33-3.67] vs. 0.86 [0.48-1.21], P = 0.028) than [18F]FDG PET/CT.

Conclusions

These findings suggest that [68Ga]Ga-FAPI-04 PET/CT has potential value in RCC diagnosis. Further studies are warranted to validate these results. Advances in knowledge Clinical utility of [68Ga]Ga-FAPI-04 in RCC remains unclear, and there are not many similar studies in the literature. We evaluated the role of [68Ga]Ga-FAPI-04 in diagnosing RCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHumansMiddle AgedAgedPilot ProjectsPositron Emission Tomography Computed TomographyFluorodeoxyglucose F18Neoplasm Recurrence, LocalPositron-Emission TomographyFibroblastsGallium Radioisotopes

Stichwörter der Autor:innen

PET/CTRCC[18F]FDG[68Ga]Ga-FAPI-04

Substanzen

Fluorodeoxyglucose F18Gallium Radioisotopes

Autor:innen und Institutionen

  • Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China.
  • Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China.
  • Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan 646000, China.
  • Department of Urology, Fushun People's Hospital, Zigong, Sichuan 643000, China.
  • Department of Nuclear Medicine, Second Affiliated Hospital of Chengdu Medical College (China National Nuclear Corporation 416 Hospital), Chengdu, Sichuan 610000, China.

ORCID-Profile: Zhanwen Huang

Förderung

  • Young Talent Program of China National Nuclear Corporation
  • Sichuan Science and Technology Innovation and Entrepreneurship Seedling
  • Natural Science Foundation of Chengdu Medical College
  • China Baoyuan Research Fund
  • Sichuan Provincial Medical Youth Innovation Research

Zitieren

APA

Guo, C., Liu, Y., Yang, H., Xia, Y., Li, X., Chen, L., Feng, Y., Zhang, Y., Chen, Y., & Huang, Z. (2024). A pilot study of [68Ga]Ga-fibroblast activation protein inhibitor-04 PET/CT in renal cell carcinoma. British Journal of Radiology. https://doi.org/10.1093/bjr/tqae025

Vancouver

Guo C, Liu Y, Yang H, Xia Y, Li X, Chen L, et al. A pilot study of [68Ga]Ga-fibroblast activation protein inhibitor-04 PET/CT in renal cell carcinoma. British Journal of Radiology. 2024. doi:10.1093/bjr/tqae025

BibTeX
@article{Guo2024,
  author = {Guo, Chunmei and Liu, Ya and Yang, Haozhou and Xia, Yuxiao and Li, Xue and Chen, Liming and Feng, Yue and Zhang, Yan and Chen, Yue and Huang, Zhanwen},
  title = {A pilot study of [68Ga]Ga-fibroblast activation protein inhibitor-04 PET/CT in renal cell carcinoma},
  journal = {British Journal of Radiology},
  year = {2024},
  doi = {10.1093/bjr/tqae025}
}
Kostenlos starten →